Brief: Calliditas Announces Primary Endpoint Successfully Met In Phase 3 Nefigard Trial Evaluating Nefecon® In IGA Nephropathy
13/03/2023 03:10
March 12 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* CALLIDITAS ANNOUNCES PRIMARY ENDPOINT SUCCESSFULLY MET IN
PHASE
3 NEFIGARD TRIAL EVALUATING NEFECON® IN IGA NEPHROPATHY
* CALLIDITAS THERAPEUTICS AB SAYS PLANS TO FILE FOR FULL
APPROVAL
FROM FDA, AND SUPPORT FILING FOR FULL APPROVAL WITH EC AND UK
MHRA DURING 2023
Source text for Eikon: ID:nPn7X4wYMa
Further company coverage: CALTX.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations